Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$93.54

-1.12 (-1.18%)

07:55
10/18/17
10/18
07:55
10/18/17
07:55

BioMarin to host analyst day

Analyst Day to be held in New York on October 18 at 8 am. Webcast Link

  • 18

    Oct

  • 26

    Oct

  • 06

    Nov

  • 28

    Feb

BMRN BioMarin
$93.54

-1.12 (-1.18%)

10/06/17
GSCO
10/06/17
INITIATION
Target $124
GSCO
Buy
BioMarin resumed with a Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on BioMarin with a Buy and $124 price target.
09/21/17
PIPR
09/21/17
NO CHANGE
Target $113
PIPR
Overweight
Piper increasingly confident in BioMarin after management meetings
Piper Jaffray analyst Christopher Raymond remains a buyer of BioMarin Pharmaceutical after hosting investor meetings with management. The analyst is increasingly confident that the company's R&D day will provide "incremental and derisking data across the development portfolio." He believes pegvaliase will continue to "work its way into the stock" ahead of its potential approval in the first half of 2018. Raymond keeps an Overweight rating on BioMarin with a $113 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $93
RBCM
Sector Perform
BioMarin initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay started BioMarin with a Sector Perform rating and $93 price target .
09/14/17
PIPR
09/14/17
NO CHANGE
PIPR
Overweight
BioMarin's pegvaliase approval 'slightly derisked,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond was "incrementally positive" on BioMarin following the news that the FDA is not planning to hold an AdCom for pegvaliase, as he believes this means the FDA is less likely to reject the drug and less likely they are overly focused on the safety of the drug. Raymond maintained an Overweight rating, noting approval of pegvaliase has been slightly derisked. Note that on Wednesday night, Raymond assumed coverage of BioMarin and upgraded the shares to Overweight from Neutral.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.